- Home
- MCO vs SNY Comparison
MCO vs SNY Comparison
Compare MCO & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MCO | SNY |
|---|---|---|
| Founded | 1900 | 1994 |
| Country | United States | France |
| Employees | N/A | 74846 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.7B | 116.8B |
| IPO Year | 1998 | N/A |
Fundamental Metrics
Financial Performance| Metric | MCO | SNY |
|---|---|---|
| Price | $469.54 | $45.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 6 |
| Target Price | ★ $550.63 | $61.50 |
| AVG Volume (30 Days) | 1.8M | ★ 4.3M |
| Earning Date | 05-21-2026 | 01-01-0001 |
| Dividend Yield | 0.87% | ★ 3.46% |
| EPS Growth | ★ 21.40 | N/A |
| EPS | ★ 13.67 | N/A |
| Revenue | ★ $4,204,100,000.00 | N/A |
| Revenue This Year | $8.55 | $2.62 |
| Revenue Next Year | $7.72 | $6.38 |
| P/E Ratio | $34.49 | ★ $6.14 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $378.71 | $44.62 |
| 52 Week High | $546.88 | $60.12 |
Technical Indicators
Market Signals| Indicator | MCO | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 51.15 | 37.34 |
| Support Level | $402.28 | N/A |
| Resistance Level | $498.90 | $49.28 |
| Average True Range (ATR) | 12.82 | 0.72 |
| MACD | 5.47 | -0.18 |
| Stochastic Oscillator | 79.81 | 8.66 |
Price Performance
Historical ComparisonAbout MCO Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed-income securities. The ratings segment, Moody's Investors Service, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's profit and often (depending on bond issuance levels) a majority of the firm's revenue. The other segment, Moody's Analytics, consists of decision solutions, research and insights, and data and information.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.